Arrowstreet Capital
SUPN icon

Arrowstreet Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Arrowstreet Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$393K Sell
7,595
-176,093
-96% -$8.97M ﹤0.01% 1703
2025
Q4 		$9.13M Sell
183,688
-42,722
-19% -$2.08M 0.01% 953
2025
Q3 		$10.8M Sell
226,410
-21,567
-9% -$869K 0.01% 936
2025
Q2 		$7.82M Sell
247,977
-8,429
-3% -$270K 0.01% 989
2025
Q1 		$8.4M Buy
256,406
+81,490
+47% +$2.89M 0.01% 861
2024
Q4 		$6.32M Buy
174,916
+77,393
+79% +$2.73M 0.01% 944
2024
Q3 		$3.04M Buy
+97,523
New +$3.04M ﹤0.01% 1121
2023
Q1 		– Sell
-39,105
Closed -$1.4M – 1517
2022
Q4 		$1.4M Buy
39,105
+30,061
+332% +$1.04M ﹤0.01% 955
2022
Q3 		$306K Buy
+9,044
New +$294K ﹤0.01% 1161
2020
Q4 		– Sell
-179,631
Closed -$3.74M – 2528
2020
Q3 		$3.74M Buy
179,631
+22,313
+14% +$506K 0.01% 1290
2020
Q2 		$3.74M Buy
157,318
+129,018
+456% +$2.85M 0.01% 1183
2020
Q1 		$509K Sell
28,300
-23,481
-45% -$493K ﹤0.01% 1525
2019
Q4 		$1.23M Buy
+51,781
New +$1.26M ﹤0.01% 1286
2019
Q2 		– Sell
-35,836
Closed -$1.26M – 1685
2019
Q1 		$1.26M Buy
+35,836
New +$1.33M ﹤0.01% 1258
2016
Q4 		– Sell
-9,667
Closed -$239K – 2428
2016
Q3 		$239K Buy
+9,667
New +$219K ﹤0.01% 1390
2016
Q1 		– Sell
-70,600
Closed -$949K – 1515
2015
Q4 		$949K Buy
+70,600
New +$1.09M ﹤0.01% 1003

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's SUPN Position: Q1 2026 in Review

Arrowstreet Capital reduced its Supernus Pharmaceuticals (SUPN) stake by 96% in Q1 2026, selling an estimated $8.97M and leaving 7,595 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #1703.

Arrowstreet Capital first reported a position in SUPN in Q4 2015 and has held it in 16 quarters since. The position peaked at $10.8M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Arrowstreet Capital held 7,595 shares of Supernus Pharmaceuticals worth $393K as of Q1 2026.
  • Arrowstreet Capital sold 176,093 Supernus Pharmaceuticals shares in Q1 2026, an estimated $8.97M.
  • Supernus Pharmaceuticals made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1703 holding.
  • Arrowstreet Capital first reported a position in Supernus Pharmaceuticals in Q4 2015 and has held it in 16 quarters since.
  • Arrowstreet Capital's Supernus Pharmaceuticals position peaked at $10.8M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.